Αρχειοθήκη ιστολογίου

Τρίτη 27 Μαρτίου 2018

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Palmer, DH; Ma, YT; Peck-Radosavljevic, M; Ross, P; Graham, J; Fartoux, L; Deptala, A; ... Meyer, T; + view all Palmer, DH; Ma, YT; Peck-Radosavljevic, M; Ross, P; Graham, J; Fartoux, L; Deptala, A; Studeny, M; Schnell, D; Hocke, J; Loembé, A-B; Meyer, T; - view fewer (2018) A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer 10.1038/s41416-018-0051-8 . (In press).

https://ift.tt/2GeZPyE

Αναρτήθηκε από στις

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Εγγραφή σε: Σχόλια ανάρτησης (Atom)